How Pharmaceutical Companies Are Navigating Tariffs and Trade Wars

The pharmaceutical industry is undergoing a major transformation as it adapts to shifting trade policies, rising tariffs, and supply chain vulnerabilities. Since 2024, drugmakers have responded with aggressive reshoring, global diversification, policy lobbying, and digital innovation to minimize disruption and secure access to essential medicines. Here’s how leading pharmaceutical firms are adapting in this new era of trade turbulence.

1. Supply Chain Restructuring

Reshoring and Onshoring Production

Pharmaceutical giants such as Johnson & Johnson, Eli Lilly, Merck, and Novartis have announced over $150 billion in U.S. manufacturing investments to reduce reliance on imported drugs and APIs (active pharmaceutical ingredients). Examples include:

Roche committing $50 billion to U.S. R&D and biologics manufacturing.
Novartis planning $23 billion to build seven new U.S.-based API facilities.

Diversifying API Sources

Drugmakers are reducing overdependence on China and India by expanding sourcing to regions like Ireland, South Korea, and Mexico. Ireland’s pharmaceutical exports to the U.S. jumped up to 400% in Q1, largely driven by stockpiling ahead of anticipated tariff hikes.

Vertical Integration

Some firms are acquiring or partnering with upstream API producers and packaging firms to gain greater control over their supply chains, mitigate tariff exposure, and improve agility.

2. Financial and Operational Adjustments

Absorbing Costs and Planning Price Adjustments

Companies initially absorbed rising tariff-related costs but are now warning of upward pressure on drug prices. For example:

Johnson & Johnson anticipates $400 million in additional tariff costs for 2025.
Boston Scientific expects a $200 million impact from Canadian and Mexican tariffs on medical devices.
Pfizer has initiated $7.7 billion in cost-saving programs by 2027, including operational cuts and realignment of R&D pipelines.

Stockpiling Critical Supplies

To avoid immediate disruptions, U.S. pharmacies and wholesalers are stockpiling essential generics like antibiotics and over-the-counter drugs. The spike in Irish exports reflects this strategy.

3. Policy Advocacy and Lobbying

Securing Tariff Exemptions
Industry groups have successfully lobbied for temporary exemptions for many pharmaceutical products under the U.S. blanket tariffs. However, these exemptions are under review and may expire, raising concerns about potential shortages of generics if tariffs are reimposed.

The American Hospital Association has warned that permanent tariffs could lead to shortages of generic drugs in the U.S., endangering patient access and increasing costs.

Opposition to Sector-Specific Tariffs
Trade groups such as BIO argue that proposed tariffs on Chinese-made APIs could impact over 70% of member companies. CEOs from leading firms, including Johnson & Johnson’s Joaquin Duato, advocate for domestic tax incentives as a more sustainable alternative to tariffs.

4. Strategic Partnerships and Mergers

Joint Ventures and Technology Transfer
To navigate tariff rules while accessing new technologies, some pharmaceutical firms are forming joint ventures in tariff-neutral countries. These partnerships enable technology transfers without triggering import duties, particularly for sensitive biologics and APIs.

Acquisitions and Logistics Expansion
Companies are acquiring contract manufacturers and logistics providers to strengthen in-house capabilities and reduce external dependency. For example, firms like Thermo Fisher have expanded their cold-chain logistics capacity to better manage the complexity of tariff-disrupted supply routes.

5. Innovation and R&D Shifts

Cold Chain and Logistics Technology
Pharmaceutical firms are investing in ultra-cold storage systems, IoT-based monitoring tools, and AI-driven logistics optimization. These innovations are essential for transporting temperature-sensitive biologics and vaccines under evolving global tariff conditions.

Personalized Medicine and Smaller Shipments
To reduce tariff exposure on bulk goods, companies are shifting toward personalized medicine models such as gene and cell therapies. These treatments often require smaller, patient-specific shipments, which are less affected by broad tariff categories.

6. Challenges and Risks

High Reshoring Costs
While companies are investing billions into reshoring production, building and validating new domestic API facilities can take 5–10 years. The U.S. currently produces just 12% of its APIs, making a full transition away from foreign sources a costly and time-consuming process.

Retaliatory Tariffs and Export Risk
Retaliatory measures from China and others, including tariffs on U.S. medical exports, threaten to reduce global market access. For instance, Canada had previously threatened to impose a 25% tariff on certain U.S. medical devices, affecting revenue and regional competitiveness.

Regulatory Fragmentation
Pharma companies face mounting compliance burdens from divergent trade policies and regulatory systems. Adapting to U.S., EU, and regional frameworks adds delays and cost—especially when shifting production or sourcing strategies.

7. Company Responses

Johnson & Johnson
The company is actively lobbying for tax incentives instead of tariffs to strengthen domestic manufacturing. J&J expects $400 million in tariff-related costs for 2025 and is expanding U.S.-based production to insulate itself from trade disruptions.

Novartis
With a $23 billion investment in U.S. manufacturing, Novartis is building seven new domestic facilities focused on APIs and specialty drugs. The move aims to reduce dependence on Chinese ingredients and achieve regulatory certainty within the U.S. market.

Pfizer
To mitigate tariff impact, Pfizer is executing $7.7 billion in global cost cuts through 2027, including trimming R&D and streamlining manufacturing. The company has also enhanced sourcing strategies and explored regional manufacturing partnerships.

Roche
Roche is investing $50 billion in U.S. R&D and biologics production. Its strategy includes securing domestic sources for advanced therapies and building production infrastructure to bypass tariff-related delays.

Summary Table: Company Strategies

Company	Strategy	Impact
Johnson & Johnson	Lobbying, U.S. production expansion	Offsetting $400M in tariff costs
Novartis	$23B domestic API investments	Reducing Chinese API reliance
Pfizer	$7.7B cost cuts, supplier diversification	Boosting sourcing flexibility
Roche	$50B R&D and production in U.S.	Securing biologics supply chains

Pharmaceutical companies are navigating tariff risks through a layered approach that balances short-term countermeasures, like stockpiling and lobbying, with long-term strategies including reshoring, supply chain diversification, and manufacturing innovation. Major players like Johnson & Johnson, Pfizer, Novartis, and Roche are investing tens of billions into domestic production and digital transformation to future-proof their operations. However, the challenges—high costs, complex tech transfers, regulatory delays, and global material dependencies—make rapid adaptation difficult. The sector’s resilience will hinge on sustained investment, policy clarity, and collaborative innovation across the public and private sectors.

References

Why overpay for visibility? TRADLINX saves you 40% with transparent per–Master B/L pricing. Get 99% accuracy, 12 updates daily, and 80% ETA accuracy improvements, trusted by 83,000+ logistics teams and global leaders like Samsung and LG Chem.